3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
34
Gastrointestinal
19
Thoracic
10
Tumor-Agnostic
5
Gynecologic
5
Genitourinary
4
Other solid neoplasm
3
CNS
3
Sarcoma
2
Dermatologic
2
Head & Neck
1
Conditions
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
166
Cisplatin
112
Cetuximab
76
Nivolumab
52
Carboplatin
51
Fluorouracil
48
Paclitaxel
42
Docetaxel
37
Gemcitabine
30
Radiotherapy
28
Capecitabine
19
Cyclophosphamide
18
durvalumab
17
Injections
17
lenvatinib
16
atezolizumab
16
cemiplimab
15
spartalizumab
13
fludarabine
13
avelumab
12
Ipilimumab
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
11
Oxaliplatin
10
Gefitinib
10
tremelimumab
9
Drug Therapy
9
tislelizumab
8
epacadostat
8
budigalimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
trastuzumab deruxtecan
×
Head & Neck
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled